Literature DB >> 32162823

Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study.

Inbar Raber1, Sarah Warack2, Jaya Kanduri1, Abby Pribish1, Anuradha Godishala3, Arielle Abovich3, Anna Orbite2, Sujithraj Dommaraju3, Morgan Frazer2, Mary Linton Peters4, Aarti Asnani3.   

Abstract

BACKGROUND: The fluoropyrimidines, 5-fluorouracil (5-FU) and capecitabine, are commonly used chemotherapeutic agents that have been associated with coronary vasospasm.
METHODS: In this retrospective case-control study, we identified patients at our institution who received 5-FU or capecitabine in 2018. We compared characteristics of patients who experienced cardiotoxicity with controls. We described phenotypes and outcomes of cardiotoxic cases.
RESULTS: We identified 177 patients who received fluoropyrimidines. After adjudication, 4.5% of the cohort met the criteria for cardiovascular toxicity. Coronary artery disease was more common among cases than controls (38% vs. 7%, p < .05). There was also a trend toward increased prevalence of cardiovascular risk factors in cases compared with controls. Most cardiotoxic cases had chest pain, although a minority of cases presented with nonischemic cardiomyopathy.
CONCLUSION: Cardiotoxicity phenotypes associated with fluoropyrimidine use are not limited to coronary vasospasm. Cardiac risk factors and ischemic heart disease were highly prevalent among patients with cardiotoxicity. © AlphaMed Press 2019.

Entities:  

Keywords:  Capecitabine; Cardiotoxicity; Fluorouracil

Mesh：

Substances：

Year:  2019        PMID： 32162823      PMCID： PMC7066698          DOI： 10.1634/theoncologist.2019-0762

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  11 in total

Review 1.  Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature.

Authors:  Michael R Grunwald; Lynn Howie; Luis Alberto Diaz
Journal:  J Clin Oncol       Date:  2011-12-05       Impact factor: 44.544

2.  Sex-Related Differences in Vasomotor Function in Patients With Angina and Unobstructed Coronary Arteries.

Authors:  Ahmed Aziz; Henrik Steen Hansen; Udo Sechtem; Eva Prescott; Peter Ong
Journal:  J Am Coll Cardiol       Date:  2017-11-07       Impact factor: 24.094

Review 3.  Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.

Authors:  Anne Polk; Merete Vaage-Nilsen; Kirsten Vistisen; Dorte L Nielsen
Journal:  Cancer Treat Rev       Date:  2013-04-10       Impact factor: 12.111

4.  Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.

Authors:  Thierry Lecomte; Jean-Marc Ferraz; Franck Zinzindohoué; Marie-Anne Loriot; David-Alexandre Tregouet; Bruno Landi; Anne Berger; Paul-Henri Cugnenc; Raymond Jian; Philippe Beaune; Pierre Laurent-Puig
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

5.  In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle.

Authors:  M Mosseri; H J Fingert; L Varticovski; S Chokshi; J M Isner
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

6.  Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

Authors:  K E Caudle; C F Thorn; T E Klein; J J Swen; H L McLeod; R B Diasio; M Schwab
Journal:  Clin Pharmacol Ther       Date:  2013-08-29       Impact factor: 6.875

7.  Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.

Authors:  Jenica N Upshaw; Anne O'Neill; Joseph R Carver; Eileen P Dimond; Crystal S Denlinger; Sheetal M Kircher; Lynne I Wagner; Bonnie Ky; Joanna M Brell
Journal:  Clin Colorectal Cancer       Date:  2018-08-20       Impact factor: 4.481

8.  Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm.

Authors:  Suparna C Clasen; Bonnie Ky; Rupal O'Quinn; Bruce Giantonio; Ursina Teitelbaum; Joseph R Carver
Journal:  J Gastrointest Oncol       Date:  2017-12

9.  Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.

Authors:  Christos Kosmas; Manolis S Kallistratos; Petros Kopterides; John Syrios; Helias Skopelitis; Nicolaos Mylonakis; Athanasios Karabelis; Nicolas Tsavaris
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-17       Impact factor: 4.322

10.  Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.

Authors:  Wen Wee Ma; Muhammad Wasif Saif; Bassel F El-Rayes; Marwan G Fakih; Thomas H Cartwright; James A Posey; Thomas R King; Reid W von Borstel; Michael K Bamat
Journal:  Cancer       Date:  2016-09-13       Impact factor: 6.860
View more
  7 in total

1.  In Reply.

Authors:  Inbar Raber; Mary Linton Peters; Aarti Asnani
Journal:  Oncologist       Date:  2020-06-17

2.  Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems.

Authors:  Chiara Lestuzzi; Lucia Tartuferi; Elda Viel; Angela Buonadonna; Emanuela Vaccher; Massimiliano Berretta
Journal:  Oncologist       Date:  2020-06-17

3.  Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise.

Authors:  Chiara Lestuzzi; Davide Stolfo; Antonino De Paoli; Alberto Banzato; Angela Buonadonna; Ettore Bidoli; Lucia Tartuferi; Elda Viel; Giulia De Angelis; Sara Lonardi; Roberto Innocente; Massimiliano Berretta; Francesca Bergamo; Alessandra Guglielmi; Gianfranco Sinagra; Joerg Herrmann
Journal:  Oncologist       Date:  2022-03-04       Impact factor: 5.837

4.  Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis.

Authors:  Yajie Lu; Shizhou Deng; Qiongyi Dou; Wei Pan; Qingqing Liu; Hongchen Ji; Xiaowen Wang; Hong-Mei Zhang
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

5.  The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm.

Authors:  Amna Zafar; Zsofia D Drobni; Ramya Mosarla; Raza M Alvi; Matthew Lei; Uvette Y Lou; Vineet K Raghu; Sean P Murphy; Maeve Jones-O'Connor; Sarah Hartmann; Hannah K Gilman; Colin D Weekes; John R Clark; Jeffrey Clark; Lawrence Blaszkowsky; Erica Tavares; Tomas G Neilan
Journal:  JACC CardioOncol       Date:  2021-03-16

6.  Capecitabine-mediated heart failure in colorectal cancer: a case series.

Authors:  Erin N McAndrew; Davinder S Jassal; Benjamin A Goldenberg; Christina A Kim
Journal:  Eur Heart J Case Rep       Date:  2021-03-02

Review 7.  Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer.

Authors:  Juan C Lopez-Mattei; Eric H Yang; Maros Ferencik; Lauren A Baldassarre; Susan Dent; Matthew J Budoff
Journal:  JACC CardioOncol       Date:  2021-12-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.